The Slower Antibody Response in Myelofibrosis Patients after Two Doses of mRNA SARS-CoV-2 Vaccine Calls for a Third Dose
Fabio Fiorino,
Anna Sicuranza,
Annalisa Ciabattini,
Adele Santoni,
Gabiria Pastore,
Martina Simoncelli,
Jacopo Polvere,
Sara Galimberti,
Stefano Auddino,
Claudia Baratè,
Francesca Montagnani,
Vincenzo Sammartano,
Monica Bocchia,
Donata Medaglini
Affiliations
Fabio Fiorino
Laboratory of Molecular Microbiology and Biotechnology, Department of Medical Biotechnologies, University of Siena, 53100 Siena, Italy
Anna Sicuranza
Hematology Unit, Department of Medical Science, Surgery and Neuroscience, Azienda Ospedaliero Universitaria Senese, University of Siena, 53100 Siena, Italy
Annalisa Ciabattini
Laboratory of Molecular Microbiology and Biotechnology, Department of Medical Biotechnologies, University of Siena, 53100 Siena, Italy
Adele Santoni
Hematology Unit, Department of Medical Science, Surgery and Neuroscience, Azienda Ospedaliero Universitaria Senese, University of Siena, 53100 Siena, Italy
Gabiria Pastore
Laboratory of Molecular Microbiology and Biotechnology, Department of Medical Biotechnologies, University of Siena, 53100 Siena, Italy
Martina Simoncelli
Hematology Unit, Department of Medical Science, Surgery and Neuroscience, Azienda Ospedaliero Universitaria Senese, University of Siena, 53100 Siena, Italy
Jacopo Polvere
Laboratory of Molecular Microbiology and Biotechnology, Department of Medical Biotechnologies, University of Siena, 53100 Siena, Italy
Sara Galimberti
Section of Hematology, Department of Clinical and Experimental Medicine, University of Pisa, 56126 Pisa, Italy
Stefano Auddino
Laboratory of Molecular Microbiology and Biotechnology, Department of Medical Biotechnologies, University of Siena, 53100 Siena, Italy
Claudia Baratè
Section of Hematology, Department of Clinical and Experimental Medicine, University of Pisa, 56126 Pisa, Italy
Francesca Montagnani
Department of Medical Sciences, Infectious and Tropical Diseases Unit, Azienda Ospedaliero Universitaria Senese, University of Siena, 53100 Siena, Italy
Vincenzo Sammartano
Hematology Unit, Department of Medical Science, Surgery and Neuroscience, Azienda Ospedaliero Universitaria Senese, University of Siena, 53100 Siena, Italy
Monica Bocchia
Hematology Unit, Department of Medical Science, Surgery and Neuroscience, Azienda Ospedaliero Universitaria Senese, University of Siena, 53100 Siena, Italy
Donata Medaglini
Laboratory of Molecular Microbiology and Biotechnology, Department of Medical Biotechnologies, University of Siena, 53100 Siena, Italy
Immunization with mRNA SARS-CoV-2 vaccines has been highly recommended and prioritized in fragile subjects, including patients with myelofibrosis (MF). Available data on the vaccine immune response developed by MF patients and the impact of ruxolitinib treatment are still too fragmented to support an informed decision on a third dose for this category of subjects. Here, we show that 76% of MF patients develop spike-specific IgG after the second mRNA SARS-CoV-2 vaccine dose, but the response has a slower kinetics compared to healthy subjects, suggesting a reduced capability of their immune system to promptly react to vaccination. A reduced ACE2/RBD binding inhibition activity of spike-specific antibodies was also observed, especially in ruxolitinib-treated patients. Our results, showing slow kinetics of antibody responses in MF patients following vaccination with mRNA SARS-CoV-2 vaccines, support the need for a third vaccine dose.
